Efficacy of baricitinib for refractory large-vessel vasculitis

Rheumatology (Oxford). 2021 Nov 3;60(11):e389-e391. doi: 10.1093/rheumatology/keab541.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Acute-Phase Proteins / analysis
  • Aorta* / diagnostic imaging
  • Aorta* / pathology
  • Azetidines / administration & dosage*
  • Biopsy / methods
  • Computed Tomography Angiography / methods
  • Drug Resistance
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Janus Kinase Inhibitors / administration & dosage
  • Middle Aged
  • Positron Emission Tomography Computed Tomography / methods
  • Purines / administration & dosage*
  • Pyrazoles / administration & dosage*
  • Subclavian Artery* / diagnostic imaging
  • Subclavian Artery* / pathology
  • Sulfonamides / administration & dosage*
  • Treatment Outcome
  • Vasculitis* / diagnosis
  • Vasculitis* / drug therapy
  • Vasculitis* / immunology
  • Vasculitis* / physiopathology

Substances

  • Acute-Phase Proteins
  • Azetidines
  • Immunosuppressive Agents
  • Janus Kinase Inhibitors
  • Purines
  • Pyrazoles
  • Sulfonamides
  • baricitinib